Lyra therapeutics reports fourth quarter and full year 2021 financial results and provides corporate update

Watertown, mass., march 9, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ent) passages and other diseased tissues, today reported financial results for the quarter ended december 31, 2021, and highlighted recent accomplishments and upcoming milestones.
LYRA Ratings Summary
LYRA Quant Ranking